Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers
Press release content from Business Wire. The AP news staff was not involved in its creation. Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers February 11, 2021 GMT Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines (Photo: Business Wire) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2021-- Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced a research ...
Source: apnews.com